{"task_id": "96469044715fdfb4", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 197/464)", "text": "cesses progressing\nrapidly\n0%\nDead\n186\nLung Cancer\n\n--- Page 208 ---\nDIAGNOSTIC AND PROGNOSTIC ISSUES (CONT\u2019D)\nEASTERN CO OPERATIVE ONCOLOGY GROUP\n(ECOG) PERFORMANCE STATUS\n\u0002 0\nnormal. KPS 100%\n\u0002 1\nlimited activity, otherwise ambulatory. KPS\n80 90%\n\u0002 2\nresting <50% of day. KPS 60 70%\n\u0002 3\nresting >50% of day. KPS 40 50%\n\u0002 4\nbed bound. KPS 10 30%\n\u0002 5\ndead. KPS 0%\nADVERSE PROGNOSTIC FACTORS\n\u0002\nGENERAL\npoor performance status (ECOG >1),\ninvoluntary weight loss (>5%), advanced stage,\nSCLC\n\u0002\nPOOR OUTCOME AFTER SURGERY\npoor performance\nstatus, weight loss (>5%), low FEV1, low PaO2,\nrecent history of smoking\nPROGNOSIS OF SMALL CELL LUNG CANCER\nlim\nited stage 20 40% 2 year survival, 16 24 months\nmedian survival, extensive stage <5% 2 year survival,\n6 12 months median survival. Median survival post\nrelapse 4 months\nMANAGEMENT\nNON SMALL CELL LUNG CANCER\n\u0002\nSTAGE IA\nlobectomy/pneumonectomy\n\u0002\nSTAGE IB\nlobectomy/pneumonectomy. Con\nsider adjuvant chemotherapy (cisplatin vinorel\nbine \u00034) if high risk features (e.g. >4 cm, high\ngrade)\n\u0002\nSTAGE II\nlobectomy/pneumonectomy + adju\nvant chemotherapy (cisplatin vinorelbine \u00034)\n\u0002\nSTAGE IIIA (N2 disease)\nconcurrent chemoradia\ntion (cisplatin etoposide \u00034), followed by either\npneumonectomy/lobectomy or radiation boost\n\u0002\nSTAGE IIIA (unresectable) AND IIIB\nno surgery.\nConcurrent\nchemoradiation (cisplatin etopo\nside \u00034) with potential chance of cure. Can con\nsider sequential chemo radiation but may have\nreduced chance of cure\n\u0002\nSTAGE IV\npalliative radiation should be admi\nnistered before chemotherapy if patients present\nwith hemoptysis, SVC syndrome, severe bone pain,\nor obstructive pneumonia. Palliative chemother\napy (cisplatin pemetrexed \u00034 (for non squamous\nhistologies), cisplatin gemcitabine \u00034 (for squa\nmous histology), cisplatin vinorelbine \u00034, or car\nboplatin paclitaxel \u00034) \u0006 bevacizumab. For pati\nents who have not progressed after 4 cycles of\nplatinum based induction chemotherapy, consider\nmaintenance pemetrexed until disease progres\nsion. For recurrent disease after platinum based\ntherapy, consider docetaxel (for squamous cell\nMANAGEMENT (CONT\u2019D)\nhistology), pemetrexed, or erlotinib (for adenocar\ncinoma histology)\nSMALL CELL LUNG CANCER\n\u0002\nLIMITED\nSTAGE\nradiation + concurrent che\nmotherapy (cisplatin + etoposide \u00034) + prophy\nlactic cranial irradiation if good partial/complete\nresponse\n\u0002\nEXTENSIVE STAGE\npalliative chemotherapy (cis\nplatin + etoposide \u00034, cisplatin + irinotecan \u00034,\netoposide \u00034) + prophylactic cranial irradiation\nif partial/complete response. For recurrent disease\nafter platinum based therapy, consider topotecan,\ncisplatin + irinotecan \u0006 ifosfamide, gemcitabine +\nirinotecan, gemcitabine + paclitaxel\nTREATMENT ISSUES\nSMOKING CESSATION\nfor smokers of <20 pack\nyear, the risk of developing lung cancer decreases\nsignificantly after 15 years of abstinence, but still\nslightly higher than non smokers\nNON RESECTABLE DISEASE CRITERIA (stage IIIB or\ngreater)\ndistant metastasis, mediastinal LN metas\ntasis, trachea/contralateral main bronchi involve\nment, SVC obstruction, malignant pleural effusion,\nrecurrent laryngeal nerve paralysis, SCLC (unless\nvery early)\nCONTRAINDICATIONS TO CHEST RADIATION\nsignificant pre existing lung disease, cardiomyopa\nthy, connective tissue disease (SLE, scleroderma),\nprior radiation to same body region, pregnancy\nCONTRAINDICATIONS TO BEVACIZUMAB\nsqua\nmous cell carcinoma, hemoptysis, uncontrolled cere\nbral metastases, non healing wounds, uncontrolled\nhypertension/proteinuria, bleeding diatheses, recent\ntrauma/surgery\nPREDICTIVE FACTORS FOR EGFR INHIBITORS\nclinical factors include women, Asian, never smokers,\nand adenocarcinoma. With all 4 factors, response rate\n50% (compared to 10% normally). Pathologic predic\ntive factors include EGFR mutation and high EGFR\ngene copy number\nRelated Topics\nDyspnea (p. 3)\nHorner\u2019s Syndrome (p. 13)\nSVC Syndrome (p. 228)\nSolitary Pulmonary Nodule (p. 13)\nSmoking Cessation (p. 418)\nSuperior Vena Cava Syndrome (p. 228)\nPre Operative Assessment (p. 422)\nLung Cancer\n187", "text_length": 4027, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 197/464)", "type": "chunk", "chunk_index": 196, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.516950", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.517682", "status": "complete", "chunks_added": 3}